Your fact-checks will appear here
FDA enforcement actions against products claiming to treat or prevent Alzheimer's disease
The so‑called “Sanjay Gupta honey pill regimen” is not a verified medical protocol promoted by Dr. Gupta but a recurring online scam that uses AI‑generated videos and fake endorsements to sell supplem...
The claim that is endorsed by is not legitimate: multiple fact-checkers report fabricated articles and doctored ads using Carson’s image or name, and Carson’s representatives say he never developed, e...
The materials supplied show regulatory enforcement against companies that marketed unproven cognitive or Alzheimer’s products and a stream of consumer complaints about a product named Neurocept, but t...
There is no credible evidence that has released a consumer “dementia product” that reverses Alzheimer’s disease; widely circulated stories about Musk-backed that “reverse dementia” are proven scams or...
Human clinical research testing for cognition is sparse and heterogeneous: a few small randomized trials and case reports have tested various honeys (including Tualang and unspecified “honey” blends) ...
The public record compiled in the provided reporting shows and enforcement focused on and the presence of unapproved drug ingredients in “” supplements generally, with concrete actions like refunds an...
has framed —most prominently —as an important but limited advance: they can modestly slow disease progression by targeting and clearing amyloid plaques, but they are not cures and carry nontrivial ris...
safety recommendations for anti‑amyloid monoclonal antibodies such as lecanemab (Leqembi) and donanemab (Kisunla) center on intensive imaging surveillance for (ARIA), pre‑treatment risk stratification...
There is no reliable reporting in the provided sources showing that publicly recommended or discussed the Alzheimer’s drugs memantine or donepezil by name in interviews or speeches; fact‑checks instea...
TauRx’s earlier Phase III trials of LMTM (leuco‑methylthioninium/HMTM/LMTX) repeatedly failed their prespecified primary endpoints, but the company highlighted statistically significant effects in sma...
Dementia "medicine" today divides into long-standing symptom-managing drugs and a new generation of disease-modifying biologics that slow—but do not cure—Alzheimer’s disease; clinicians stress early d...
Patients prescribed 2025 FDA‑approved Alzheimer’s drugs face variable but often substantial out‑of‑pocket exposure that depends on the drug’s list price, Medicare cost‑sharing rules, required diagnost...
Two monoclonal antibodies—lecanemab and donanemab—have randomized-trial evidence of modest slowing of cognitive decline at 18 months and emerging longer-term data for lecanemab suggesting continued, s...
Randomized, double‑blind trials of the newest FDA‑approved Alzheimer’s drugs—principally the anti‑amyloid monoclonal antibodies lecanemab (Leqembi) and donanemab (Kisunla)—have demonstrated statistica...
Randomized controlled trials and systematic reviews provide modest, sometimes consistent evidence that Bacopa monnieri can improve certain memory domains after weeks to months of use, while huperzine ...